While the benefits of quicker access to new treatments are clear, they must be weighed against the potential risks. Rapid approval processes can sometimes lead to insufficient testing, increasing the risk of unforeseen side effects or ineffective treatments reaching the market. Regulatory bodies must ensure that the accelerated processes do not compromise the rigorous evaluation necessary to confirm the safety and efficacy of new treatments.
